Welcome to our dedicated page for Twist Bioscience SEC filings (Ticker: TWST), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Twist Bioscience Corporation (NASDAQ: TWST) SEC filings page on Stock Titan provides access to the company’s official disclosures filed with the U.S. Securities and Exchange Commission. As a mid-cap growth and value biotech company focused on synthetic DNA tools and a silicon-based DNA synthesis platform, Twist uses its filings to report financial performance, governance changes and other material events.
Investors can review current and historical 8-K reports, which for Twist have included announcements of quarterly and full-year financial results, as well as board and committee changes. For example, recent 8-K filings describe the release of financial results for specific quarters and fiscal years, and the appointment of a new director to the board and audit committee, along with associated compensation arrangements.
In addition to 8-Ks, users can access Twist’s annual reports on Form 10-K and quarterly reports on Form 10-Q via the SEC feed. These documents typically contain detailed discussions of results of operations, risk factors, and business descriptions related to Twist’s synthetic DNA platform, research tools and geographic operations. Proxy materials and equity compensation plan disclosures can also be reviewed to understand governance practices and incentive structures.
Stock Titan enhances these filings with AI-powered summaries that highlight key points, helping readers quickly interpret complex documents such as lengthy 10-Ks or detailed 10-Qs. Real-time updates from EDGAR ensure that new filings appear promptly, while Form 4 and related insider transaction reports can be monitored to see equity awards and other reportable insider activity. Together, these resources support a deeper understanding of TWST’s regulatory disclosures and corporate developments.
Twist Bioscience Corporation (TWST) has filed a Form 144 notice covering the potential sale of 3,189 common shares through Fidelity Brokerage, with an estimated market value of $90,453. The proposed trade window opens on 04 Aug 2025. The company reports 59,916,141 shares outstanding, so the planned sale represents roughly 0.005 % of the float—immaterial at the corporate level.
The shares derive from restricted-stock that vested on 01 Aug 2025 and are held in the account of Patrick Finn. Over the previous three months, Finn has already sold 27,118 shares for total gross proceeds of $894,853, indicating an ongoing disposition program.
Form 144 is only a notice; execution, timing, and price may vary, and the filer certifies no undisclosed material adverse information. No operating, earnings or guidance data accompany this filing.
FAQ
What is the current stock price of Twist Bioscience (TWST)?
What is the market cap of Twist Bioscience (TWST)?
